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ABSTRACT 
Background: Cystic fibrosis (CF) is the most common life shortening autosomal recessive 
inherited disease affecting Caucasian people. The two main clinical characteristics of CF 
are progressive pulmonary disease and pancreatic insufficiency. The goal of airway 
clearance technique (ACT) is to improve ventilation and mucociliary clearance. The overall 
purpose of this thesis was to evaluate and compare the effects of Non Invasive Ventilation 
(NIV) and positive expiratory pressure (PEP) on airway clearance, and to find out if the use 
of NIV during an exercise test would reduce carbon dioxide (CO2) retention compared to 
oxygen (O2) supplementation. To explore at what point after ACT spirometry should be 
performed, and to determine whether there are interindividual and intraindividual 
differences, were also studied. To describe the patients´experiences of using NIV as an 
adjunct to ACT was also a purpose. Paper I, a prospective study. Twenty-four patients with 
CF. In adult patients, mean forced expiratory volume in one second (FEV1) improved 30 min 
(p=0.001), 1 h (p=0.002), and 2 h (p=0.006) after physiotherapy compared to baseline; in 
pediatrics it improved after the session (n.s.). There were no intraindividual variations but 
interindividual differences were found. Paper II, a prospective randomized study. Thirty-two 
patients with CF completed a 3 month long randomized trial comparing NIV with standard 
PEP. There was a significant reduction in lung clearance index (LCI) following NIV 
compared with PEP (p=0.01). Paper III, a qualitative study. Eighteen patients with CF were 
interviewed about their experiences using NIV during chest physiotherapy. Semi-structured 
interviews were conducted and analyzed using qualitative content analysis. “Becoming 
friends with NIV” emerged as a theme and came to represent a learning process. To facilitate 
this learning process, different factors should be taken into account until NIV is experienced 
as meningful. Paper IV, a prospective crossover study, compared O2 supplementation and 
NIV during an exercise test. Eight patients with CF completed an incremental test on a 
treadmill (using the Bruce protocol) while comparing standard treatment O2 with NIV. NIV 
showed a decreased rise in transcutaneous pressure of carbon dioxide (tcPCO2), maintaining 
the level within the normal reference values compared to O2 (p=0.01). 
Conclusion: The point at which to perform a lung function test after an ACT is different for 
adults and children. NIV has shown to be as effective as other ACTs. Exercise tests showed 
tcPCO2 remaining within the normal reference values with NIV but not with PEP. All 
participants completed the NIV treatment without major discomfort and experienced NIV as 
meaningful after becoming friendly with the NIV.  
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1 INTRODUCTION 
Chest physiotherapy is considered a basis of care for patients with CF. The clinical picture of 
CF has changed over time with an increased life expectancy and increased expectations of 
people with CF to have a normal life. The strategies used in physiotherapy for CF have also 
changed dramatically over the years, moving from postural drainage and percussion toward an 
individualized regimen. The physiotherapist's main purpose in helping patients with CF is to 
manage the symptoms and progression of their condition.  The daily treatment 
burden is still challenging. 
1.1 HISTORY AND EPIDEMIOLOGY 
Cystic fibrosis is the most common inherited autosomal recessive life shortening disease today 
(1). In the late 1800s, it was referenced in a poem as “the child will soon die whose brow tastes 
salty when kissed”. Fanconi was the first to describe the disease in 1936, listing symptoms 
displaying in the pancreas and lungs, while in 1938 Andersen first mentioned cystic fibrosis of the 
pancreas (1, 2).  
In 1948, Paul di Sant´ Agnese identified an excess of sodium and chloride in the sweat of patients 
with CF (3), a finding which became the basis for the sweat test (4). In 1985, the gene was 
localized to chromosome 7. The gene was cloned in 1989 and the protein identified as the cystic 
fibrosis transmembrane conductance regulator (CFTR) (5). Defects in the CFTR affects ion 
transport in epithelial cells in the airways, sweat ducts, pancreatic ducts, intestines, biliary tree and 
vas deferens (6).  
In Sweden, the incidence of CF is 1/5600 live-births. Of the CF population alive in 1999, 45 % 
were over 18 years of age. Of those born in 1991, 95 % were estimated to survive their 25th 
birthday (7). 614 patients were registered in the annual Swedish report in 2013, of which 64 % 
were adults (8).  
1.2 GENETICS AND PATHOGENESIS 
The gene affected is located on chromosome 7, which encodes the cystic fibrosis 
transmembrane conductance regulator (CFTR). The CFTR corresponds to a cyclic adenosine 
monophosphate (cAMP) regulated chloride channel that is found in the secretory epithelial cells 
(9).  
The major mutation is called F508del and accounts for 70 % of the disease alleles. More than 
1,900 mutations have been discovered in the CF gene. Different mutations are associated with 
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different disease symptoms. Genotype phenotype correlation is highest for the pancreatic status. 
Some mutations in the CF gene do not cause any of the symptoms associated with CF (10). 
A total of of 306 mutations have been annotated on the CFTR2 website (11): 
 CF-causing: 272 
 Mutations of varying clinical consequence: 19 
 Non-CF-causing: 12 
 Mutations of unknown significance: 3 
Many of these mutations can be divided into five classes depending on their demonstrated 
molecular consequences (12). Affected patients will have two copies of the mutant CFTR gene, 
one inherited from each parent. The normal CFTR gene is part of a family of proteins that share 
transmembrane transport functions. CFTR regulates the activity of chloride and sodium channels 
at the cell surface as well as other apical membrane channels related to ion transport (5).  
 
1.3 PATHOPHYSIOLOGY 
The level of clinical complications in patients with CF is largely determined by the associated 
class of mutation (13).  
 
1.3.1 Respiratory System 
The hydration of the airway surface layer (ASL) fluid in the airways is regulated by the ion 
channels that control the amount of salt and water on the airway surfaces. The epithelia is 
capable of both absorbing fluid and secreting fluid, depending on the direction of the salt 
transport across airway epithelia. As the concentration of sodium chloride (NaCl) inside the 
ASL is essentially isotonic, knowing the overall amount of NaCl in the ASL is essential for 
determining the total fluid volume of the ASL (14). 
The gene that encodes CFTR is associated with reduced chloride (Cl
-
) secretion and increased 
sodium (Na
+
) reabsorption, which results in reduced water content of the secretions. The 
periciliary liquid of the secretions is isotonic with an osmolarity that allows water to reabsorb 
with Na
+
 from the lumen. This leads to reduced depth and increased viscosity of the periciliary 
liquid, which in turn results in a slower airway clearance and the trapping of inhaled bacterias in 
the thick secretion (15). 
The bronchial glands consist of mucous cells (secrete mucins) and serous cells (secrete 
antibacterials such as lyzozyme and other substances). The volume of the glands and secretory 
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cells are increased in CF patients. Healthy people normally produce more than 10 mL of mucus 
per day, which serves as a defense and protection of the lower respiratory tract (16).  
The plasma exudation in CF patients is associated with decreased mucociliary transport as well 
as mucus plugs. The airflow obstruction arising due to retained secretions increases the work of 
breathing (WOB), produces ventilation-perfusion mismatch, and results in gas exchange 
abnormalities. Additionally, secretions retained in the airway can serve as a source of infection 
and inflammation. Between the production of mucus and its clearance exists an important 
balance that have to work perfectly in order to avoid the progression of this disease (17). 
(Figure 1).  
 
 
Figure 1. Pathophysiology of the CF disease 
 
If the balance between production and clearance of secretion does not work properly, patients 
with CF may experience bacterial infection. Pseudomonas aeruginosa remains the main pathogen 
in adults, but other bacteria such as Staphylococcus aureus and Haemophilus influenzae have also 
been shown to play an important role in the lung disease. Nasal polyps are common in CF and are 
probably a consequence of chronic inflammation; however, their specific etiology is unclear. In 
patients with CF, sinonasal involvement can exacerbate lung disease, the upper airways serving as 
a bacterial reservoir. The decline in the amount of CFTR to bind with the bacteria contributes to 
the bacterial loads in the lungs (18).  
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As the inflammation and mucus obstruction of the airways increase, it becomes more difficult 
for air to pass through, leading to expansion of the alveoli and air trapping. The destruction of 
the pulmonary parenchyma due to chronic bacterial infection with mucus retention results in 
increased pulmonary arterial pressure and right-sided heart failure or cor pulmonale. The 
pulmonary inflammation persists and eventually becomes chronic, causing hypertrophy of the 
bronchial arteries and ultimately hemoptysis (13).  
 
As the disease progresses, the FEV1 decreases, and the WOB and respiratory muscle load 
increase. As a result, patients with CF develop a compensatory mechanism of a rapid shallow 
breathing pattern in an attempt to reduce this increase in load. This breathing strategy may 
maintain the level of minute ventilation, but alveolar hypoventilation, characterized by 
hypercapnia and hypoxemia, may also develop (19). The most severe respiratory signs and 
symptoms are due to the production of increased levels of thickened mucus that cause 
inflammation and obstruction of the airways (13).  
 
Cystic fibrosis is associated with a substantial variability in phenotype (clinical picture), from 
severe with early lung disease to mild form (20, 21). It is described as a progressive lung 
obstructive disease with chronic inflammation and infections that results in tissue destruction. 
The end-stage of the disease is characterized by respiratory failure with severe hypoxia, 
pulmonary hypertension and secondary cardiac complications (22). 
 
 
1.3.2   Hematopoietic System 
The hematopoietic system is also affected in patients with CF, characterized by iron deficiency 
anemia generally, and as a result of chronic hemoptysis in some cases. Pseudomonas 
aeruginosa is a common bacteria that colonizes the lungs and/or upper airways and robs iron from 
the host for growth purposes (13).  
Iron deficiency has been reported in one third of all patients with CF. Data suggests that iron 
absorption is increased with exocrine pancreatic deficiency and that administration of pancreatic 
enzymes may impair oral iron absorption (23). 
 
1.3.3 Gastrointestinal System 
There have also been findings of gastrointestinal problems in patients affected with CF, this due 
to the inability of the pancreas to supply digestive enzymes to the intestine. As the volume of 
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secreted pancreatic enzymes decreases, the pancreas secretes thick mucus that obstructs the 
pancreatic ducts and in such a way further shrinks the volume of enzymes that can be secreted. 
This situation leads to malabsorption of fat and affects absorption of the fat-soluble vitamins A, 
D, E, and K (24). The distal part of the CF patient's intestine may dilate and fill with fecal 
content. The condition manifests itself as vomiting, abdominal distention, anorexia, pain in the 
right lower quadrant of the abdomen, and cramping with a decrease or no change in bowel 
movements. The name for this condition is distal intestinal obstruction syndrome (DIOS) and is 
a result of deficient secretion of salt and water from the intestinal epithelium leading to 
dehydration of the intestinal material (25). 
Some patients also present gastroesophageal reflux disease due to hypersecretion of gastric acid 
and hyposecretion of bicarbonate. The presence of gastroesophageal reflux disease may 
additionally aggravate bronchial reactivity (13). Gastroesophageal reflux has also been known to 
worsen respiratory symptoms (26). 
Even though hepatobiliary disease is the most common non-pulmonary cause of mortality in 
CF, only about 33 % of CF patients present clinically significant hepatobiliary disease. The 
abnormal activity or absence of CFTR decreases bile fluidity, causing accumulation and 
precipitation of hyperviscous biliary secretions in the intrahepatic tree. Bile accumulates in the 
biliary ducts leading to cholangiocyte and hepatocyte injury, stimulating focal fibrosis. This in 
turn results in the accumulation of toxic bile acids in the liver, depletion of hepatic antioxidants, 
and liver cell injury. Repeated liver cell injury may activate hepatic stellate cells and lead to 
hepatic fibrosis and in some cases cirrhosis. Liver transplantation is restricted to patients with 
difficult complications of portal hypertension and/or end-stage liver failure in good nutritional 
state (27). Modern treatment may have had a positive influence on liver disease, seeing as how 
it has become less common and progressive as time has gone by (28). 
 
1.3.4 Endocrine System 
Cystic fibrosis–related diabetes (CFRD) is the most common comorbidity in CF, occurring in 
20 % of adolescents and 40–50 % of adults (29). The main cause of CFRD is a reduced insulin 
secretion capacity combined with a variable state of insulin resistance (30).The patients displaying 
cystic fibrosis–related diabetes still require a high-energy diet. The glucose metabolism is affected 
by many factors specific to CF, like severe dehydration, administration of corticosteroids, 
malabsorption, chronic infection, poor nutrition, increased energy expenditure, slowed 
gastrointestinal transit time, and liver dysfunction (13). 
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1.3.5 Sweat Glands 
Due to the decreased functional levels of the protein CFTR, which regulates the salt content in 
sweat, patients with CF may experience excessive salt loss from intense heat or after extreme 
physical exercise (13).  
1.3.6 Reproductive System 
Puberty is delayed in both men and women (13).  Most of the men with CF are sterile due to 
lacking or having malformed vas deferens. However, their sperm production is normal. 
Advances in the field of reproductive medicine has allowed for the procurement of viable sperm 
and facilitated fertilization and pregnancy in CF patients (31).  
Women with CF are fertile but often require more time to become pregnant. Mucus plugs in the 
oviduct and thicker cervical mucus result in decreased sperm movement. Although women with 
CF thus have reduced fertility, many of them can become mothers spontaneously (32).  
 
 
1.4 DIAGNOSIS 
The measurement of sweat electrolyte concentrations has been the mainstay of diagnosing CF 
since a standardized procedure, known as the Gibson-Cooke method, was established in 1959 (4). 
A CF diagnosis can be made if the sweat Cl
-
 value is ≥60 mmol/L and the subject shows 
symtoms consistent with CF. A sweat Cl
-
 value of ≤40 mmol/L is likely to be within the normal 
range, and CF is considered to be unlikely though not excluded. Intermediate levels between 30 
and 60 mmol/L may be associated with atypical forms of CF and should undergo extensive 
CFTR mutation analysis (i.e., expanded panel of CFTR mutations, evaluation for deletions or 
gene sequencing) (33-35). Cystic fibrosis diagnosis is made on the basis of two positive sweat 
tests – or a positive mutational analysis - and either a sibling or first cousin with CF, pancreatic 
insufficiency or lung disease, i.e. symptoms consistent with CF (33).  
There are other tests used in diagnosing CF, such as nasal potential difference (NPD) analyses 
which provide a direct and sensitive evaluation of sodium Na
+
 and chloride Cl
-
  transport in 
nasal epithelial cells by assessing their bioelectric properties. Intestinal current measurements 
(ICM) can be used in similar ways. Rectal biopsies are used where the CFTR protein is highly 
expressed in the apical membrane of intestinal epithelial cells (36). 
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1.5 TREATMENT 
The three pillars of treatment are: antibiotic therapy, nutrition and airway clearance. A 
multidisciplinary team should work together to provide the best care to this group of patients; the 
care should be centralized (37).  
1.5.1 Medical treatment 
The eradication of bacteria should be the main goal until chronic colonization has been 
established. When the patient has become chronically colonized, they are treated with antibiotics 
“on demand”, i.e in case of slight symtoms of deterioration. Most of the antibiotics are 
administrated intravenously. However, aerosol antibiotics have been introduced and allow the 
patient to achieve a high-level antibiotic concentration in the lower airways, minimizing the 
systemic effects (38). In order to reduce the number of hospital admissions, home intravenous 
antibiotic treatment was introduced in Sweden as early as 1985, enabling most patients to work or 
attend school while receiving the antibiotics (39). 
1.5.2 Nutrition 
The treatment of pancreatic insufficiency with pancreatic enzyme supplementation is necessary in 
patients with CF who have a pancreatic insufficiency, i.e. around 85 %. Fat malabsorption leads to 
less absorption of the fat-soluble vitamins. Vitamins A, D, E and K should be supplemented. 
Patients with CF also show disturbances in their lipid metabolism, leading to low levels of 
essential fatty acids (40, 41). Nutritional supplements have been advocated in malnourished CF 
patients. Attempts to improve the nutritional status of affected children have included caloric 
supplements and enteral feeding, usually with elemental formulas. Aggressive nutritional therapy 
in CF is based on the premise that it improves pulmonary functions (42). 
Nutrional supplementation is an ongoing necessity due to the patients' abnormal enterohepatic 
circulation of bile, increased metabolism and increased caloric demand due to severe lung disease 
(38). Additionally, requirements are elevated because of increased losses due to malabsorption, 
nitrogen losses in the feces and sputum, and a potentially alterated protein metabolism (43).  
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1.5.3 Physiotherapy and airway clearance technique 
The world confederation for physical therapy (WCPT) defines physical therapists as people 
specialized in the developing, maintaining and restoring of people´s functional abilities and 
ability to move throughout their entire lifespan (44). Chest physiotherapy is a treatment where 
the goal is to improve breathing by the indirect removal of mucus, something which is urgent in 
CF patients. The role of the physiotherapist working with patients with chronic lung diesases is 
to relieve symptoms through ACTs and preserve their physical condition and lung function 
through different physical training exercises (45). Chest physiotherapy has for a long time 
played an important role in assisting in the clearance of airway secretions and is usually 
commenced as soon as a CF diagnosis has been made. However, chest physiotherapy may be 
unpleasant, uncomfortable, and time-consuming. Early chest physiotherapy relied on techniques 
which required the assistance of another person, such as a physiotherapist or relative, and which 
included postural drainage, percussion, vibration, and shaking performed by the assistant as 
well as, and huffing or coughing. More recently, several self-administered alternatives to these 
conventional techniques have been developed. These include the active cycle of breathing 
techniques (ACBT), forced expiration technique (FET), autogenic drainage (AD), positive 
expiratory pressure (PEP), flutter, high frequency chest compression (HFCC) and exercise. 
Conventional chest physiotherapy includes any combination of the following: postural drainage, 
percussion, chest shaking, huffing, and directed coughing (46).  
The airways of CF patients are plugged with a thick and sticky mucus. Therefore, clearance of 
secretions plays a prominent role in early therapy during the onset of the disease. Airway 
clearance techniques in combination with inhalation of mucolytic agents are neccesary as a 
daily treatment. The technique is taught as soon as the diagnosis has been confirmed and is 
thereafter continuosly evaluated. The treatment is performed twice a day, lasting from 45 
minutes to one hour. Inhalation therapy has shown to improve sputum clearance.  The sticky 
properties of the mucus are identified by differents components, including free DNA, 
polymerized actin, and the mucins themselves, all of which are highly viscous. Cleaving free 
DNA into smaller pieces reduces its viscosity. Recombinant DNA technology has made it 
possible to produce human DNase (Pulmozyme®), a new drug developed specifically for CF 
which gives minimal adverse effects and gives rise to an improvement in pulmonary function 
and reduction in the number of exacerbations (47). Aerosol hypertonic saline solution has been 
shown to result in a modest increase in pulmonary function and reduction in exacerbations as 
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well, presumably by temporarily drawing water into the airway to dislodge the mucus (48). 
Some other nebulized or orally given mucolitics agents, such as thiol derivatives (Ambroxol and 
N-acetylcysteine), have also been used, but there is no evidence for recommending the use of 
either in patients with CF (49). However, oral N-acetylcysteine has shown to maintain lung 
function in patients with CF (50). 
The airway lumen is affected in CF not only by secretions but also by airway edema, smooth 
muscle hypertrophy, and bronchoconstriction. The use of inhaled steroids, though never proven 
effective in CF in controlled clinical trials, may reduce airway edema. Bronchodilators such as 
β-adrenergic agonists, intended to relax airway smooth muscle, are administered mainly before 
hypertonic saline, though not all patients have responded to them in direct testing and some 
patients have actually shown paradoxical decreases in pulmonary function (probably because 
the airway wall had already been sufficiently damaged) (38). 
The International Physiotherapy Group for Cystic Fibrosis (IPG/CF) (51) describes several 
different ACTs, all of which have been proven to be effective. Healthier patients with CF can 
augment mucus clearance with aerobic exercise, which stimulates deep breathing and cough 
(52). Positive expiratory pressure (PEP) is defined as breathing with a positive expiratory 
pressure of 10 to 25 cm H20. High pressure PEP (hPEP) is a modification of the above PEP 
technique which includes a full forced expiration against a fixed mechanical expiratory 
resistance (53). Active cycle of breathing techniques (ACBT) include relaxation or breathing 
control, FET, thoracic expansion exercises and may also include postural drainage or chest 
clapping (54). Autogenic Drainage (AD) is another technique whereby the mucus is moved by 
airflow in different parts of the airways (55). Physical exercise increases the tidal volume (VT) 
with deeper breath and in this way improves the mucus clearance (46). Oscillating devices 
including flutter or cornet produce an oscillatory PEP effect. The thoracic oscillation provides 
oscillation to the chest wall (46). 
The key to any device used to clear secretions is that it meets the criterion based on respiratory 
physiology. This criterion states: increase absolute peak expiratory flow (PEF) to move 
secretions towards the oropharynx. Mucus transport can be achieved by expiratory airflow 
during forced expiration, as well as tidal breathing. The peak expiratory flow/peak inspiratory 
flow ratio (PEF/PIF) needs to be 41.1 to clear secretions (56). 
Airway clearance has been shown to hold short-term effects for patients with CF, but the long-
term effects of no airway clearance remain unknown. However, the absence of evidence does 
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not necessarily imply the absence of benefit (57). Conventional chest physiotherapy is as 
effective as other forms of airway clearance. Patients like their independence, and therefore any 
technique, which they themselves can use - such as PEP - is preferred. There is not enough 
evidence to conclude, one way or the other, that any ACT is better or worse than any other 
technique (58). 
1.5.4 Noninvasive ventilation 
Recent years have shown NIV, as an adjunct to ACT, to help patients to clear sputum more 
easily than other ACTs. This remains especially true for those patients who are very ill and have 
difficulties expectorating sputum (58-61).   
Positive pressure ventilatory assistance can be delivered in the form of inspiratory pressure 
support (pressure pre-set) systems, which deliver a variable volume according to a pre-set 
inspiratory pressure. Alternatively, a set VT (volume pre-set) system may be used, which 
delivers a fixed VT irrespective of the airway pressure required to generate this volume. The 
earliest NIV trials employed volume pre-set equipment. However, later trials have used pressure 
pre-set devices, primarily due to their simplicity and the comfort of the individual. The NIV 
machines entrain room air and allows for additional oxygen to be entrained into the ventilatory 
tubing, or directly into the mask (59). 
The purposes of ventilation include: correct hypoxaemia and hypercapnia (type II respiratory 
failure), improve tidal volumes, decrease fatigue and the WOB, and treat nocturnal 
hypoventilation. Non invasive ventilation has been used for patients with CF since the early 
1990s, when it was described as a holding treatment for patients on the transplant waiting list. 
Non invasive ventilation is still occasionally used as a 'bridge to transplant’, but there are many 
other indications such as an adjunct to airway clearance therapy in CF (62). The use of NIV 
reduces hypoventilation and improves gas exchange by increasing minute ventilation and 
reducing the WOB. Clinically, NIV has also been used as an adjunct to ACTs in CF patients 
with moderate to severe disease. The exact mechanism by which NIV may assist airway 
clearance is still unclear. It has been postulated that decreased respiratory muscle fatigue and 
prevention of airway closure during prolonged expirations may ultimately lead to an increase in 
effective alveolar ventilation, better compliance with airway clearance and increased sputum 
clearance (63). 
Many CF patients show increased energy expenditure, oxygen desaturation, fatigue and 
dyspnoea during chest physiotherapy. Since NIV reduces respiratory muscle work and prevents 
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respiratory muscle fatigue, it could thus be considered a good alternative for very ill patients 
who need the extra support during airway clearance (63, 64). In several studies, participants 
reported greater ease of expectoration,
 
less breathlessness and less fatigue when standard chest 
physiotherapy treatment was assisted by NIV. Additionally, participants reported that they 
preferred treatment with NIV compared to standard chest physiotherapy (64, 65).  
The improvements in breathlessness, fatigue and ease of expectoration may be at least partly 
explained by the preservation of respiratory muscle strength during NIV-assisted treatment 
compared to standard chest physiotherapy. This effect on respiratory muscle strength suggests that 
patients with CF may be able to perform airway clearance manoeuvres with less effort and/or 
tolerate more effective ACTs with the support of NIV, especially when it is most required during 
an acute exacerbation (63, 64, 66, 67). 
 
1.6 OUTCOME 
Pulmonary function and exercise capacity are two outcomes to be considered with regards to the 
survival chances of CF patients (68). Also used are additional surrogate endpoints of lung disease, 
as for example chest computed tomography (69). 
1.6.1 Lung function test 
Pulmonary function testing is a method that helps in establishing data that assists in predicting 
deterioration in clinical status in patients with CF.  
The most common outcome measure used by physiotherapists to monitor their interventions and 
evaluate their practice is FEV1. The pulmonary function test most commonly performed to 
assess respiratory physiotherapy interventions is the forced spirometry, the volume and/or flow 
of air that can be inhaled and exhaled as a function of time. The procedure consists of maximal 
inspiration followed by a complete exhalation. First, the patient should exhale until he or she 
reaches the functional residual capacity (FRC), after which they should be instructed to inhale 
rapidly and completely. The mouthpiece should be placed in the patient’s mouth and indications 
should be given for the patient to blow as much and as fast as possible and to keep blowing until 
the lungs have been totally emptied. Spirometry is a cost-effective, simple, reliable, valid and 
easy to interpret measure. The most commonly used pulmonary function parameter is the FEV1, 
followed by forced vital capacity (FVC) and ratio between FEV1/FVC. Measurements are taken 
considering the patient’s gender, age, height, weight and race and are then compared against 
predicted values (70). 
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1.6.2 Single and multiple breath washout 
There are some pulmonary tests that are more sensitive than forced spirometry, such as single 
(SBWO) and multiple breath washout (MBWO). A nitrogen washout can be performed with a 
single nitrogen breath, or multiple ones. Both tests can estimate FRC and the degree of 
nonuniformity of gas distribution in the lungs, but the multiple breath test more accurately 
measures absolute lung volumes (71, 72).  
Single breath washout and MBW assess ventilation distribution inhomogeneity at differing lung 
volumes. The most widely used is the nitrogen (N2) SBW test, which involves a vital capacity 
(VC) manoeuvre performed at low constant flow (400–500 mLs.-1): exhalation to residual 
volume (RV), inhalation of 100 % oxygen gas (O2) to total lung capacity (TLC), then washout 
during exhalation from TLC to RV, where phase III is measured over the mid portion of the 
expirogram (73). 
Multiple breath washout assesses ventilation distribution inhomogeneity during tidal breathing 
from FRC, by examining inert gas clearance over a series of breaths. Exogenous gas washout 
requires an initial wash-in phase. Multiple breath washout requires only passive cooperation and 
minimal coordination, but is more time consuming. The lung clearance index (LCI) is the most 
commonly reported MBW index, and is defined as the number of FRC lung turnovers required 
to reduce alveolar tracer-gas concentration to a given fraction of its starting concentration, 1/40 
(2.5 %). LCI is calculated as the ratio of cumulative expired volume (CEV) to FRC, with CEV 
defined as the sum of all expiratory VT over the washout. LCI=CEV/FRC (73). 
 
1.7 RATIONALE BEHIND THE THESIS 
Patients with CF need to undergo airway clearance therapy twice a day. Frequently they also 
need to take part in physical exercise in order to maintain their lung function. Both airway 
clearance therapy and physical exercise has to be performed more often as the patients 
deteriorate. As the disease progresses and lung function declines, the ACT increases energy 
expenditure, fatigue and dyspne in the patient. Non invasive ventilation could therefore be 
beneficial to severely ill patients during airway clearance therapy. It is important to study the 
effects of NIV as an adjunct to ACT and a tool used during exercise in severely ill CF patients 
in order to individualize the treatment. To our knowledge, no studies have so far investigated 
the effects of NIV as an adjunct to ACT using high-pressure ventilation, the CF patients' 
experience with NIV treatment nor how NIV assisted exercise displays in CF patients.  
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2 AIM 
The overall purpose of this thesis was to evaluate the use of NIV as an airway clearance treatment 
compared to PEP, and as ventilatory support during exercise in people with CF. Additionally, we 
sought to explore at what point after physiotherapy spirometry should be performed. Yet another 
objective was to evaluate the experience of using NIV as an adjunct to ACT. 
  
The specific goals were to: 
 Identify at what time point after a physiotherapy session spirometry should be performed 
in order to obtain the highest result compared to baseline, and to determine if there are 
interindividual and intraindividual differences in children and adults with CF. (Study I) 
 Evaluate and compare the effects of NIV and PEP on airway clearance. (Study II) 
 Describe adult patients’ views on and experiences of using NIV as an adjunct to ACT. 
(Study III) 
 Find out if the use of NIV during an exercise test would reduce CO2 retention when 
compared to O2 supplementation in subjects with CF. (Study IV) 
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3 MATERIAL AND METHODS 
3.1 STUDY POPULATION AND DESIGN 
Study I was a prospective study. The criterion for inclusion was a confirmed diagnosis of CF. 
The exclusion criteria consisted of upper airway infection, cognitive dysfunction, the presence 
of nasal polyps, associated asthma, a proven inability to perform a technically acceptable lung 
function test and inability to stay at the clinic for the required four hours. Patients were included 
consecutively, drawn from the out-patient clinic at the Stockholm CF Center. Of the 28 patients 
screened, 24 were enrolled in the study. Of the 24 patients included, 16 were adults (mean age 
329 years) and 8 were children (mean age 152 years). 
 
Study II was a prospective randomized study with a control group (PEP treatment). The 
inclusion criteria were patients with CF at Stockholm CF Centre, over18 years of age and with a 
FEV1 between 20 % and 69 % of the predicted value. The exclusion criteria were the presence 
of a symptomatic upper airway infection, cognitive dysfunction, cardiorespiratory instability, 
infection with Burkholderia cepacia complex, gastroesophageal reflux, a history of 
pneumothorax or massive haemoptysis. Out of the 45 patients who met the inclusion criteria, 32 
agreed to participate in the study. The mean age in the NIV group was 28 (±11) years and 33 
(±9) years in the PEP group. The 13 patients who declined to participate did so because they 
lived too far away from the hospital.  
 
Study III was a qualitative study applying content analysis with an inductive approach. The 
inclusion criteria were adults with CF being treated at Stockholm CF center, with a FEV1 of 20-
69 % of the predicted value or having undergone a lung transplant during the period 2012-11-01 
to 2013-11-01, and adult patients who used NIV as an adjunct to ACT. The exclusion criteria 
were colonization of Burkholderia cepacia and/or Methicillin-resistant Staphylococcus aureus 
(MRSA) carriers and adults who did not master the Swedish language in speech and writing.  
Twenty-nine adults used NIV as an adjunct to ACT, 18 adults (aged between 20-54 years) met the 
inclusion criteria and agreed to participate in the study. Eleven adults who used NIV were not 
included for different reasons: either they did not master the Swedish language (n = 1), were <18 
years (n = 2) or lived outside of Stockholm (n = 8).  
 
Study IV was a crossover study comparing NIV with O2 treatment. The inclusion criteria were 
patients with CF at Stockholm CF center, over 18 years of age, with a FEV1 between 20 and 69 % 
of the predicted value and who had developed alveolar hypoventilation during the physical 
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performance test and used oxygen supplementation during training. The exclusion criteria 
included the presence of a symptomatic upper airway infection characterized by fever less than 
one month before entering the study, cognitive dysfunction, cardio-respiratory instability, 
infection with Burkholderia cepacia complex, gastroesophageal reflux, a history of pneumothorax 
or massive hemoptysis. Of the 13 patients who met the inclusion criteria, 8 patients agreed to 
participate in the study. The mean age was 33 (±12) years. (Table 1). 
 
Table 1. Baseline characteristics of the participants in Study I to IV. 
 Study I 
(n=24) 
Study II 
(n=32) 
Study III 
(n=18) 
Study IV 
(n=8) 
Age (yrs) 26 (±10) 31 (±10) 34 (±12) 33 (±12) 
Gender 
(male/female) 
17/7 16/16 9/9 3/5 
FEV1 % 61 (±30) 47 (±14) 38 (±9) 42 (±10) 
FVC % 70 (±30) 69 (±13) 63 (±13) 56 (±13) 
FEV1: forced expiratory volume in one second. FVC: forced vital capacity. 
 
3.2 PROCEDURE 
Study I, the daily physiotherapy, performed by all patients, consisted of inhalation twice a day. 
The ACTs performed by all patients consisted of autogenic drainage, PEP and huffing 
maneuvers carried out in a seated position at the same time of day for two days. One 
physiotherapist supervised and conducted all the sessions and performed the measurements 
(FEV1 and FVC).  
 
In study II patients were randomized to NIV and performed their daily physiotherapy treatment 
with the help of bilevel PAP. The control group went through the same protocol but instead of 
using NIV they performed their treatment with the PEP mask. The daily physiotherapy 
treatment in both groups consisted of two sessions lasting 60 minutes twice a day for three 
months. It involved the following: inhalation, AD, huffing and NIV or PEP. NIV was 
administrated with a bilevel PAP device (Vivo 40, Breas, Sweden). One single physiotherapist 
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supervised and conducted all the monthly treatment sessions. The following tests were 
performed before and after the intervention: lung function test, 6-minute walk test, sputum 
samples, inflammatory markers (blood samples), blood gases, peripheral oxygen saturation 
(SpO2), heart rate and respiratory rate. Blind test leaders and nurses performed all measurements. 
The physiotherapist test leader instructed patients to perform the six-minute walk test and 
recorded the information.  
 
Study III involved adults with CF being interviewed at Stockholm CF Center about their 
experiences of using NIV as an adjunct to ACT. Semi-structured interviews were conducted and 
analyzed in accordance with qualitative content analysis. One physiotherapist conducted the 
interviews and recorded the data; the interviews lasted between eight to twenty-eight minutes. A 
person not involved in the research group but familiar with the material transcribed the subsequent 
audio files.  
 
In study IV patients were randomized to perform a maximal exercise test on a treadmill (Bruce 
protocol) with access to supplementary O2 or NIV. After 30 minutes, they were asked to cross 
over to NIV or oxygen. The patients were instructed to walk on the treadmill with NIV or O2 
supplementation. The tests were performed on the same day with a 30 minute break (washout 
period) in between. The NIV device used was the same as in study II. A mask was used to 
administrate O2 supplementation. Two physiotherapists supervised, recorded and conducted the 
following measurements before and after the tests: lung function test as FEV1 and FVC, tcPCO2, 
BORG rating of perceived exertion (Borg RPE) scale, Rating of Perceived Dyspnea Scale (Borg 
CR-10), SpO2, respiratory rate and heart rate. Distance completed was also recorded. 
 
3.3 MEASUREMENTS 
Participants were blinded to their own results throughout the whole studies. 
3.3.1 Lung function test: spirometry and multiple breath washout. 
In study I the lung function test was performed in a seated position at the same time of day in 
accordance with American Thoracic Society/ European Respiratory Society (ATS/ERS) 
recommendations (74). Patients performed spirometry with a portable microspirometer (MS01 
Gold Standard MicroPlus, CareFusion, San Diego, California) before and immediately after 
their airway clearance session, as well as 30 min, 1, 2, and 3 h afterwards. Forced expiratory 
volume in one second and FVC were recorded as the best value out of three technically 
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satisfactory forced expirations. All patients performed the series of measurements on two 
consecutive days to identify intraindividual variations.  
 
In study II the lung function tests included whole-body plethysmography (Sendormedics, Vmax 
Encore 22, USA). Static (measuring lung volume) and dynamic (measuring flow) spirometries 
were recorded as well, LCI obtained by MBWO nitrogen (N2). The tests were performed in 
accordance with American Thoracic Society guidelines (74). The technicians at the pulmonary 
laboratory were blinded to the physiotherapy treatment of the patients. 
 
In study IV the lung function test was performed as in study I, before and after the test. Forced 
expiratory volume in one second and FVC were taken as the best value out of three technically 
satisfactory forced expirations. A portable microspirometer (MS01 Gold Standard MicroPlus, 
CareFusion, San Diego, California) was used. 
 
3.3.2 Exercise testing and physical funtion: Six-minute walk test and Bruce protocol. 
In study II a six-minute walk test was performed in accordance with the ATS (75). 
Measurements taken before and after the tests measured: SpO2, Borg RPE, Borg CR-10, heart 
rate, all parameters recorded by the physiotherapists (76, 77). 
 
Study IV saw the Bruce protocol test performed on a treadmill with NIV and O2 
supplementation. The test involved walking on a treadmill with incremental speed and gradient 
(78). Peripheral oxygen saturation, distance (meters), heart rate and respiratory rate were 
recorded before and after the test. The participants graded their perceived exertion using the 
Borg RPE and their dyspnea using the Borg CR-10 before and after the test.   
3.3.3 Qualitative content analysis 
Study III covered semi-structured interviews with adult patients, conducted based on content 
analysis. Latent and manifest content analysis was used to analyze the data. The topics included in 
the interviews were: experiences of symptoms, physiotherapy treatment with NIV, attitude 
towards and motivation to perform the daily treatment with NIV, concerns about using NIV as a 
treatment as well as future treatment. 
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3.3.4 Other measurements 
Study II collected and analysed sputum cultures, blood samples for measuring arterialized 
capillary blood gases and inflammatory parameters, once a month. 
Before each physiotherapy session, nurses blinded to the treatment of the patients measured and 
recorded the following: respiratory rate, heart rate and SpO2 using a pulse oximeter and finger 
probe (Onyx vantage, Nonin, USA). Body mass index was also recorded. 
 
Study IV measured SpO2 and heart rate using a pulse oximeter with finger probe (Onyx vantage, 
Nonin, USA), and tcPCO2 were measured and recorded during the test on the treadmill by a 
SenTec device (SenTec digital monitor V-Sign™ System, SenTec AG, Therwil, Switzerland) 
(79). 
 
3.4 STATISTICAL ANALYSES 
The results of study I and II were presented as mean values with standard deviation (SD). The 
results of study IV were presented as median and range. In all studies the level of statistical 
significance was set at p<0.05. Statistica software was used to analyse studies I and II, while study 
IV employed STATA. 
Study I used The Student t-test to compare the paired data. Study II used ANOVA General 
lineal model (GLM) to make comparisons within and between the groups. Post hoc contrast was 
used due to the interaction between NIV and LCI being significant, p = 0.02. Study IV used the 
Wilcoxon signed-rank test.  
 
3.5 QUALITATIVE ANALYSES 
Qualitative content analysis according to Graneheim and Lundman was chosen based on an 
inductive approach (80). The overall aim of the analysis was to build a model to describe the 
phenomenon in a conceptual form. In the present trial, both manifest and latent content meaning 
in the data was considered important enough to extract. Whereas manifest content means the 
encoding of the visible and obvious content of the text, latent content means encoding what the 
text talks about, the underlying meaning. Table 2 represents an example of the interpretive content 
analysis process from meaning unit to category. 
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Table 2. Example of data analysis.  
Meaning unit Condensed 
meaning unit 
Code Sub-category Category 
I would say that first you have to 
be open-minded, and you take 
over this first feeling that it is 
difficult (…) but if you go past 
the first moment, then you will 
see that it is effective. And then 
also to have patience, it is a 
boring advice. But be patient 
and deal with this as best you 
can. 
 
Be open-
minded. Be 
patient, and fight 
in the beginning 
of the treatment, 
you will see that 
the NIV is 
effective. 
 
Be 
patient 
until the 
results  
 
Tolerance 
before the 
habit 
Finding the 
rhythm 
 
 
3.6 ETHICAL APPROVAL 
The regional research ethics committee in Stockholm approved the studies. All participants gave 
their informed consent to participate. All measurements and techniques used in the differents 
studies were already part of the existing CF treatment. 
The purpose of this research was to evaluate the effects of different treatments and identify which 
one is the most beneficial for each individual. 
The principles for medical research involving human patients were considered before, during and 
after the clinical trials in order to promote respect for and protect all participants' health and rights 
(81). 
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4 RESULTS 
4.1 PULMONARY FUNCTION 
Study I, showed that the mean FEV1 in adult patients increased after each physiotherapy session, 
the statistically significant difference was found at 30 min (p< 0.001), 1 h (p<0.002), and 2 h 
(p<0,006) following physiotherapy in comparison to baseline. The mean FVC increased and 
was statistically significant at 30 min (p<0.02) and 2 h (p<0.04) following physiotherapy. 
The mean FEV1 in adult patients increased by 7 % compared to baseline (30 min after 
physiotherapy). In comparison to baseline, the highest by which the FVC mean was increased 
was 10 % (30 min after physiotherapy). The mean FEV1 and FVC in pediatric patients showed 
no statistically significant difference compared to baseline at any point, but there was a trend 
towards an increase immediately following physiotherapy. The mean increase in FEV1 in 
pediatric patients was 1 % (immediately following physiotherapy) and 2 % for FVC 
(immediately following physiotherapy) compared to baseline.  
The study identified an interindividual variation but no intraindividual; seven adults showed peak 
times after 30 minutes following chest physiotherapy whereas three children showed inmediately 
after chest physiotherapy (figure 2 and 3. Table 3).  
 
 
 
Fig 2: Number of patients peak-times. FEV1 and FVC peak time adults. FEV1: forced expiratory volume in one 
second. FVC: forced vital capacity. 
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Fig 3: Number of patients peak-times. FEV1 and FVC peak time children. FEV1: forced expiratory volume in one 
second. FVC: forced vital capacity. 
Table 3. Spirometry values before and after chest physiotherapy. 
  Adults  P Value 
 
Children p Value Total p Value 
N 16  8  24  
FEV1 56±29  70±32  61±30  
FEV1 after 58±30 .20 71±31 .69 63±30 .22 
FEV 1 30m 60±30 <.001 66±32 .12 63±30 .33 
FEV1 1 h 59±30 <.002  64±30 .11 61±30 .95 
FEV1 2 hrs 58±30 <.006 68±32 .51 62±30 .26 
FEV1 3 hrs 57±29 .39 67±28 .27 61±28 .51 
FVC 67±27  76±37  70±30  
FVC after  69±28 .53 78±37 .12 72±31 .24 
FVC 30 m  74±27 <0.02  74±32 .46 74±28 .08 
FVC 1 h  72±27 .10 75±32 .66 73±28 .22 
FVC 2 hrs  72±27 <0.04 74±31 .38 72±28 .26 
FVC 3 hrs  71±27 .15 70±27 .16 70±26 .79 
Values are expressed as mean% ± SD. FEV1: forced expiratory volume in the first second. FVC: forced vital capacity. 
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Study II showed a significant decrease in LCI following NIV treatment compared to the control 
group (p<0.01). FEV1 and FVC did not change significantly following either treatment (p = 
0.52, p = 0.25). (Table 4). 
 
Table 4. Mean (SD) lung function parameters, LCI, 6 MWT and PCO2 before and after treatment. 
 NIV 
Pre                       Post                    
PEP 
Pre                Post 
p 
value 
FEV1 (l) 1.60 (±0.5)            1.54 (±0.36)     2.10 (±0.6)      2.03 (±0.6)           .98 
FEV1% 43 (±12)                41 (±12)                          55 (±15)          54 (±13)        .52 
FVC (l) 2.82 (±0.77)          2.77 (±0.84)              3.6 (±0.9)        3.61 (±0.87)  .54 
FVC% 64 (±12)                61 (±16)    78 (±13)          78 (±12)  .25 
LCI 10.2 (±2.37)          9.20 (±2.55)        9.69 (±2.5)      9.76 (±2.5)  <.01 
6 MWT (m) 553 (±69)              559 (±95)  539 (±55)        553 (±77) .76 
PCO2(kPa) 5.10 (±0.73)          5.14 (±0.66) 5.22 (±0.42)    5.12(±0.53)                   .08 
FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, LCI: lung clearance index, 6 MWT: six 
minute walk test, PCO2: partial pressure of carbone dioxide. 
 
Study IV showed that FEV1 and FVC did not change significantly after treatment in either group.  
 
4.2 EXPERIENCE OF USING NIV 
The results revealed six categories that were summarized in the overall theme becoming friends 
with NIV (Table 5). The six categories found were:  
 Getting a sense of control and feedback: where the patients felt that the NIV gave them a 
sense of control over the disease due to being able to follow the lung volumes on the NIV 
display. 
 Getting support: the patients felt that the physiotherapist offered help depending on 
disease status. 
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  Dealing with doubts: as NIV was perceived to be a device meant only for the most 
seriously ill patients, in the beginning the patients claimed not to be that sick. This fear 
was based upon lack of information and knowledge about the NIV. 
  Finding the rhythm: in order to acclimatize to the NIV treatment, it was considered 
important to reach a level of synchronicity with the device. 
 Feeling the effects: the ability to feel the benefits of the treatment played an important role 
in the experience surrounding the NIV treatment. 
 Finding their own motivation: the motivation increased when the patients started a new 
treatment, while in turn the effects of the treatment increased the motivation even more. 
These categories could be seen to represent different aspects that the physiotherapist should keep 
in mind during the implementation of NIV. The idea of becoming friends with the NIV could be 
deduced from all the categories, and was experienced by many of the participants in our study. To 
try to view the treatment as meaningful was a form of feedback given to motivate the patients to 
use NIV. During the time the patients learned how to use the NIV, they experienced both positive 
and negative feelings. This continued until they'd learned how the treatment worked. “Becoming 
friend with NIV” could then be seen as an individual learning process occurring until the patient is 
able to see the treatment as something meaningful. 
The patients’ experiences could be summarized as follows: 
"Yes, it felt weird at first, before, you have to learn to breathe against the device. So it was a 
little difficult to get used to. Now it fits like a hand into a glove. I have learned to adapt quickly 
to the machine’s breathing ways. " (Participant 4)  
"And it comes down to finding the melody there. I discovered that when I found the melody then 
it was much easier. The melody was found, I got into the right rhythm to breathe, to find that 
now I'll come along, now I’ll breathe out here and I'll pull in and then you end up after all in 
some sort of symbiosis with the machine. And then, it was when it was at its best. "(Participant 
11) 
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Table 5. Overview of the findings: Subcategory, category and overall theme. 
Subcategory Category Theme 
Feedback of treatment 
Control of disease progression 
Getting a sense of control and feedback  
 
 
 
 
Becoming friends with 
NIV 
Individualized treatment 
Alliance with the therapist 
Getting support 
Fear of deterioration 
The machine is an obstacle 
Dealing with doubt 
Tolerance before habit 
Practice makes perfect 
Finding the rhythm 
Optimized mucus evacuation 
Saving time and more energy 
Feeling the effects 
Something new to try 
Results are worth it 
Finding their own motivation 
 
 
4.3 OTHER RESULTS 
Study II found to be no difference between a standard treatment and a bilevel PAP during the 
six-minute walk test. The partial PCO2 did not change significantly following either treatment 
(p=0.08), nor did the SpO2 or respiratory rate. The inflammatory markers, blood gases and 
sputum samples analysed monthly did not show any significant deviations from the baseline 
data, indicating that the patients were all in stable conditions during the study (Table 4). 
Study IV showed the tcPCO2 increased from 4.5 kPa to 5.43 kPa (p=0.03) after NIV and from 
4.84 kPa to 6.34 kPa (p=0.01) after O2 supplementation; i.e. the tcPCO2 increase was less in the 
NIV group (p=0.01). Heart rate increased from 86 to 150 (p=0.01) after NIV and O2 from 97 to 
153 (p=0.01) after O2 supplementation. There was found to be a significant difference between 
the groups (p=0.04) (Table 3). 
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Table 6. Median (range) lung function parameters, tcPCO2, SpO2, heart rate, Borg and Borg 
perceived exertion before and after tests using NIV and O2. 
 NIV 
Pre                       Post                    
02 
Pre                Post 
p 
value 
FEV1 (l) 1.60 (±0.5)            1.54 (±0.36)     2.10 (±0.6)      2.03 (±0.6)           .98 
FEV1% 43 (±12)                41 (±12)                          55 (±15)          54 (±13)        .52 
FVC (l) 2.82 (±0.77)          2.77 (±0.84)              3.6 (±0.9)        3.61 (±0.87)  .54 
FVC% 64 (±12)                61 (±16)    78 (±13)          78 (±12)  .25 
tcPCO2 4.5 (4-5.68)         5.43 (4.6-6.07)        4.84 (4.28-5.69)   6.34 (6.13-6.57) < .01 
SpO2 97 (92-99)            90 (90-97) 96 (94-99)        93 (91-95)          .43 
HR 86 (73-97)            150 (122-179) 97 (90-112)      153 (124-175) <.04 
Borg RPE 6 (6-6)                  15 (11-17) 6 (6-6)              15 (11-17) .28 
Borg CR-10 0 (0-2)                4.5 (3-7) 0.5 (0-3)            4 (3-8)          .51 
FEV1: forced expiratory volume in 1 second, FVC: forced vital capacity, tcPCO2: transcutaneous pressure of carbon 
dioxide, SpO2: peripheral oxygen saturation, HR: heart rate, Borg RPE: Borg rating of perceived exertion scale. Borg 
CR-10: rating of perceived dyspnea scale.  
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5 DISCUSSION 
The purpose of this thesis was to evaluate the use of NIV as an adjunct to ACT as compared to 
PEP, and as ventilatory support during exercise tests performed by people with CF. The objective 
was also to explore at what point after chest physiotherapy a spirometry should be performed, and 
to describe the experience of using NIV as an adjunct to ACT. In our studies, NIV has shown to 
be beneficial to patients with CF both as an ACT and during exercise tests.  
 
5.1 FINDINGS 
In study I the main result was the difference in FEV1 in adult patients, which was dependent on 
amount of time following the chest physiotherapy session in question. Other main findings 
included patients showing different FEV1 after their chest physiotherapy sessions with 
interindividual variations but not intraindividual variations. There was also a difference found 
between adult and pediatric patients. 
Not taking into account the role that time plays in the period following a physiotherapy session 
while designing clinical and therapeutic studies may lead to underestimation as well as 
overestimation of outcome results. In most therapeutic studies, the individual patients perform 
the lung function test at the same time of day, thereby indirectly minimizing the effect of 
physiotherapy sessions if the physiotherapy sessions are also performed at the same time of day. 
Present studies normally don't consider how chest physiotherapy may affect lung function test 
results (82). As it may be of clinical importance, determining the individual subject’s peak time 
following chest physiotherapy holds significant weight. In evaluating the effects of different 
chest physiotherapeutic sessions, the question of time as it pertains to the lung function tests 
should be considered. Determining which outcomes will be used in clinical trials is crucial for 
finding a sensitive tool to study the progress of the disease as FEV1 or LCI.  
Due to the progression of the disease, a more severe disease status in adult patients with CF is to 
be expected. In the time period following a physiotherapy session, adult patients may 
experience obstruction of the airways, while sputum that has not been evacuated may remain in 
the central airways, possibly affecting the results of the forced spirometry. This may be a 
possible reason for adults performing spirometry better 30 min or later following chest 
physiotherapy. Children may have shown better spirometry results immediately after chest 
physiotherapy due to experiencing lesser amounts of sputum and better lung function at 
baseline. The fact that pediatric patients performed somewhat worse over time might be due to 
having to perform 18 spirometry maneuvers during the same study period. It could very well 
have been difficult for the pediatric patients to remain motivated and perform at the top of their 
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game several times in a row. 
 
In study II the main finding on adult patients with CF was the significant decrease in LCI 
identified following chest physiotherapy with assisted NIV when compared to PEP during a 
three month period. Both groups maintained their lung function during the course of the study 
period, which is in agreement with previous short-term studies done on ACTs, for example, a 
standard treatment involving airway clearance breathing technique had no positive effect on 
lung function parameters (83). On the other hand, patients did manage to maintain their FEV1 
and FVC, even those with severe a disease status. In our study, the treatment period was 
established so as to be able to evaluate the long-term (12 weeks) effects of NIV treatment.  
Previous studies have shown that LCI measured by multiple breath washout represents a 
sensitive measure of ventilation inhomogeneity. FEV1 in early CF disease stages mostly reflects 
the proximal airways; LCI is considered to reflect abnormalities of the smaller airways, 
considered the site of early lung injury in CF. The lung clearance index will increase in the 
presence of airway narrowing caused by either inflammation or mucus plugging and has been 
found to be more sensitive than spirometry in the early stages of CF lung disease (84). The lung 
clearance index could be an efficient solution for the purpose of detecting changes in the small 
airways, mostly in those patients who get easily tired performing lung function tests such as the 
forced spirometry (85).  
 
The improvement in LCI shown in this study could be due to the longterm effects of NIV in 
alveolar ventilation and the prevention of airway closure during chest physiotherapy, as has 
been reported in other studies (86, 87). No adverse effects were observed during the use of NIV 
in our study. All patients performed a six-minute walk test. Even patients with severe lung 
disease managed to complete a six-minute walk test (distance completed was more than 500 m) 
(88, 89).  
 
Bilevel PAP offers many advantages, including decreasing the WOB, increasing FRC, 
improving gas exchange and improving general pulmonary function much more smoothly than 
PEP, seeing as how the device helps the subject. Positive expiratory pressure is a flow-
dependent device so the pressure can be different during the manoeuvres. When NIV is used the 
patients breathe and receive support as inspiratory and expiratory pressures (pre-setted) during 
the breathing cycle (62). 
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In study III the principal finding revealed six categories that were summarized in an overall 
theme: becoming friends with NIV.  From start until such a time the treatment begins to show 
results, there exists an interaction between the patient and the device. In keeping with the findings 
of previous studies, the participants had a positive experience using NIV as an adjunct to ACT 
(64, 65). However, the treatment required regular skill training to be useful. Patients who received 
feedback felt they obtained more control over their disease, while support adapted to the patient's 
lung condition was needed throughout the NIV treatment.  The physiotherapist's implementation 
of NIV is both a craft and a science (90). It is essential that the physiotherapist strategically 
stimulates the patient's tolerance to the new therapy through information and support (91). The 
monitoring and evaluation procedures were important tools when adapting NIV to the status of 
the participants. Airway clearance technique must be monitored, reviewed and evaluated 
frequently in order to achieve good adherence to the daily treatment routine (92, 93). To create an 
alliance between the patient and the physiotherapist was shown to be necessary when a new 
device was introduced (94). The participants displayed some doubts about the treatment at the 
beginning of the NIV therapy, based on having no previous knowledge of the new device. An 
approach involving individualized treatment and personalized learning are thus necessary when 
starting a new technique (95). As shown in other studies, NIV offers participants a subjective, 
improved and deeper mucus clearance than previous treatment techniques could, however this 
could not be measured in this study (65). Motivation was an essential factor in carrying out the 
treatment, as was a close communication between patient and physiotherapist (96).  
In the present study, to become friends with NIV constituted a learning process; during this 
process the participants had to learn about the new device, how it worked. They also required 
support from the physiotherapist. The learning process started when the NIV was introduced and 
continued until the patient felt comfortable with the treatment and experienced good effects. This 
learning process consisted of several components: continuity in learning, communication between 
patient and physiotherapist as well as monitoring how knowledge is received and interpreted (97). 
Patients´ responses may in this way help guide the implementation and ongoing delivery of NIV 
to adults with CF, in order to improve acceptance and adherence to ACT. 
In study IV the main finding was the significant decrease in elevated tcCO2 after NIV compared 
to after O2 supplementation during an incremental test on a treadmill. Both tests were performed 
on the same day with an interval of 30 minutes in between. Both groups maintained the same lung 
function during the test period. In concordance with other studies, there was no evidence to 
suggest that exercise improves lung function in terms of forced spirometry (98).  
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As has been shown in our study, the ventilatory limitation during exercise could have been 
compensated by NIV assisted exercise. During exercise, minute ventilation must be maintained in 
order to preserve the inspiratory and expiratory flow rates, something which NIV could have done 
in this study. This would have been achieved by an increase in end-expiratory lung volume 
(EELV) and a decrease in inspiratory time (TI). Airways obstructions in CF cause prolongation of 
expiratory flow and, when associated with an increased breathing frequency, may result in air 
trapping. The consequence of air trapping is compromised functioning of the inspiratory muscles 
by flattening of the diaphragm and shortening the accessory and intercostal muscles. The work 
and O2 cost of breathing are increased. More respiratory work is performed during inspiration. If 
the inspiratory muscles are disadvantaged or overworked, they will fatigue prematurely during 
progressive exercise (98). Thus ventilatory limitation during exercise in CF patients could be 
reduced using NIV.  It has been demostrated that assisted ventilation during training as Bilevel 
reduces dysponea and increaces exercise tolerance in patients with chronic obstructive pulmonary 
disease (COPD) (99). The expiratory flow limitation and increased respiratory frequency as 
decribed in COPD patients may reduce the expiratory time, resulting in increased end-expiratory 
lung volume, a condition also known as dynamic hyperinflation (DH). In such condition, tidal 
breathing takes place at lung volumes closer to total lung capacity (100). In concert with the DH, 
there is an increase in intrinsic positive end-expiratory pressure (PEEPi) and the elastic work of 
breathing (WOB): the final result is severe dyspnoea during physical effort which reduces the 
exercise tolerance (101, 102). Chronic obstructive pulmonary disease and CF are both diseases 
that cause chronic inflammation of the airways yet have distinct characteristics;COPD patients 
exhibit a reduced airway caliber, which is associated with cell damage induced by external toxic 
agents. Bronchiectasis in CF develops with recurrent damage to the airways, thus leading to 
inflammation and destruction of the muscular and elastic components of the bronchial walls (103). 
Since both diseases display chronic inflammation in the airways that limit exercise, the same 
rehabilitation programme could be used. 
Non invasive ventilation can be safely used to assist in airway clearance in adults with CF, and is 
beneficial to those with severe bronchial obstruction and reduced inspiratory muscle strength (63, 
64). After having taken part in a period of NIV-assisted training, COPD patients displayed higher 
mean training intensity and peak work rate than after unassisted training (104). Other studies have 
confirmed the benefits of performing NIV during exercise training in COPD patients (105). 
The present study showed an improvement in gas exchange, probably due to an increase inVT 
after NIV assisted training. Non invasive ventilation improves exercise capacity by unloading 
respiratory muscles and therefore allowing patients to train at higher levels of exercise intensity 
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(99). As was described in patients with COPD, the admininistration of oxygen may have 
increased the ptCO2 in the present study. Other studies have shown that excessive oxygen 
administration in turn can lead to hypercapnic respiratory failure in some patients with COPD. 
The real explanation involves two aspects: an increased V/Q mismatch and the Haldane effect 
(106).  
Finally, the present thesis have shown that NIV is beneficial as assisted-exercise support and as 
ACT in patients with CF. The results suggest that NIV should be introduced in conjunction with 
an explanation of its use and should be evaluated uninterrupted. When designing critical trials, 
one should identify and choose the most optimal time for performing the lung function tests in 
order to avoid overestimation and underestimation of the data, particulary if the subjects 
undergo chest physiotherapy. In our studies, NIV has been used as an ACT with higher 
inspiratory and expiratory pressure than in other studies, which represents a completely novel 
approach to the field (63, 64). Additionally, the application of NIV assisted exercise in CF 
hasn't been studied as much when compared to COPD, thus our study will promote and 
comprise the basis for new studies that investigate the effects of assisted ventilation during 
training (99). 
   
 
5.2 METHODOLOGICAL CONSIDERATION 
In study I, the patients were chosen from an out patient CF clinic in Stockholm. Of the 28 
patients screened, 24 were enrolled in the study. The patient group contained a small number of 
children displaying a high age variation, which may affect the result; nevertheless the 
characteristic of the patients studied was representative of our population. In study II, the 
attempt was to recruit homogenous groups representing a variation of age, gender and lung 
function; of the 45 patients screened, 32 were enrolled. The other 13 declined to participate 
because they lived too far from the hospital. Randomization was done in a stratified way in 
order to retain the same population regarding lung function in both groups. In study III, patients 
were recruited from study II, the group of patients who used NIV as an adjunct to ACT. Study 
IV included a variation of age, gender and lung function. Of the 13 patients eligible to 
participate, eight were enrolled in the study. The other five patients declined to participate, 
mainly due to lack of time and motivation. All participants in all the studies completed the 
trials.  
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Study I was a prospective study. Here, we used spirometry to measure FEV1 and FVC, seeing as 
how it is still one of the most commonly used outcome parameters and - though highly 
technology and effort dependent - is easy to perform consecutively in an out-patient setting. 
Spirometry is a valid and reliable instrument for measuring lung function (107). Subjects in the 
study had been performing spirometry every month since they were 4–5 years of age. Forced 
expiratory volume in one second is certainly one of the best and widely used markers of 
prognosis in CF. However, the measurements lack sensitivity, particularly in mild early stages 
of the disease or when looking for small changes in response to an intervention (108, 109). 
Lung function parameters as forced spirometry have been used as end points in most therapeutic 
CF trials to date. However, it has been suggested that the LCI could offer a more sensitive early 
marker and a stronger indicator of disease progression than spirometry (110). Findings about the 
effectiveness of respiratory physiotherapy interventions in CF remain controversial when FEV1 
is considered as the outcome measure in clinical trials. The accuracy and sensitivity of 
spirometry depends on a variety of factors that are difficult to control and not related to the 
intervention itself. Therefore, spirometry might be unsuitable or its reliability affected in a 
number of situations, for example if patients are unwilling or unable to collaborate. Hence, this 
measure should only be used to characterise the pulmonary function status of patients with CF 
until more sensitive devices like MBWO have been established as standard (111).  
The main limitation of the study was its size. The statistical power was calculated for the entire 
study population (children and adults) but the subanalysis was done for children and adults. As 
the population was distributed normally, a T-test was used. The time for performing the 
spirometry after ACT was chosen arbitrarily up until three hours following ACT, seeing as how 
the patients could't stay longer. Another limitation was that the subjects in the study were treated 
differently when it came to inhaled medications, a difference that may influence the results. 
 
Study II was a prospective randomized study with a control group. We used spirometry and 
MBW to measure the lung function. One disadvantage of the LCI is that completely obstructed 
lung regions do not contribute to the overall measurement since the inhaled gas does not reach 
those regions. Therefore, in patients who have completely obstructed lung regions, LCI may 
lead to underestimating the disease severity; FRC levels and computer tomography should 
consequently be used as a complement (109). The measurements chosen, like lung function test 
and the six-minute walk test, are considered valid and reliable (107, 112). To measure 
hypercapnia, arterialized capillary blood gases were used instead of arterial blood gases, i.e. the 
gold standard; however, the correlation between PH and PCO2 is high (113, 114). The validity 
of this method could be affected by the procedure or equipment used.  
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The study was powered for the detection of a 5 % difference in FEV1. Thus, the study 
population may have been too small to detect significant findings with regards to the other 
included parameters. The population was distributed normally, thus ANOVA was used to 
compare the groups. Furthermore, the present study found it ethical to involve patients with 
severe lung disease even when they were on a transplant list, since NIV is often used as a bridge 
to lung transplantation in CF patients.  Some patients used NIV in their daily treatment while 
others had to be introduced to it, this may also affect the results. A further limitation of the study 
was that, it not being possible for ethical reasons, there was no control group consisting of 
patients with no assisted chest physiotherapy. 
 
Study III had a qualitative design. Qualitative content analysis was chosen based on an inductive 
approach to analyze both manifest and latent content (80). We chose content analysis to better 
understand how the NIV is experienced by CF patients, as well as to be able to better describe 
patients´ experiences and perspectives and capture their impression of the implementation of a 
new treatment. One of the present study's strengths was that from the very start of the analysis, 
the research group worked on the material. Additionally, triangulation was used to safeguard the 
credibility of the material. The interviews were held in connection with a scheduled visit to 
Stockholm's CF center to avoid extra visits. In a qualitative approach, trustworthiness is used to 
support the arguments' worth and is of special import when using an inductive approach (115). 
The results were described alongside quotations from the interviews to facilitate the reading. 
The criterion for trustworthiness was followed, though prior understanding could affect the 
interpretation of our data.  
A possible weakness was that all researchers involved were physiotherapists; however one did not 
have any clinical experience with patients with lung diseases. The risk of researcher bias was 
considered. The interviewer, a physiotherapist who knew the patients but was not involved in the 
implementation of the treatment with NIV, may have influenced what the participants felt 
comfortable sharing. Knowing the researcher may have had a negative impact. Participants may 
have answered only what they thought the researcher wanted to hear in order to please them or 
avoid causing offense. Consideration should be given to the fact that the interviews were held in 
Swedish and all participants also lived in Stockholm. This could suggest that the results are not 
necessarily inclusive of the view of those from other cultures or patients living outside large cities. 
To minimize the risk of errors, the quotes were translated from Swedish to English by a 
physiotherapist whose first language is English. Another limitation lay in the fact that the 
interview duration was very limited, which may have affected the results. Patients with 
Burkordelia cepacia and MRSA had to be excluded seeing as there were no isolation facilities 
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where one could perform the interviews. Additionally, the patients' differing experiences with 
using NIV may have affected the results, but was taken into account before the analysis. In 
general, there were no differences in responses that could be traced back to how long the patients 
had been using the NIV. 
 
Study IV had a crossover design. Patients who participated in this study acted as their own control 
subjects when comparing O2 supplementation (standard treatment nowadays) with NIV 
treatment. The measurements chosen are considered valid and reliable. However, the study still 
had some limitations: the number of participants was very small with no control group.  On the 
other hand, the power calculation suggested that eight subjects would be enough. The population 
was not distributed normally, which is why the Wilcoxon signed-rank test was used. The tests 
(Bruce protocol) were performed twice (once with NIV and once with oxygen supplementation), a 
fact which may have affected the results, since the subjects could have felt more familiar when the 
tests were performed the second time. The Bruce test is a submaximal test that is considered valid 
and realiable (116). The transcutaneous measurements are too valid and reliable and were used to 
measure hypercapnia, despite arterial blood gases being considered the gold standard (117). The 
results obtained during the present study may have been different if the subjects were already 
hypercapnic at the beginning of the test. The strength of the study was that only two 
physiotherapists were needed to record all the measurements, hence ensuring the data collection.  
 
5.3 CLINICAL IMPLICATIONS 
The results from the present studies show that NIV can be useful as an ACT and in reducing 
tpCO2 during an incremental exercise test in adult patients with CF. The same group of patients 
described having a positive experience of the new technique and would recommend its use to 
other groups of patients. Further results showed that spirometry as FEV1 is still a useful parameter 
but need to be measured within a specific timeframe following ACT. 
Study I showed the importance of detecting the peak value after spirometry. The practical 
implementation of this study is important for obtaining a reliable value following the ACT, which 
then may be used as an outcome in clinical trials – both considering the effect of airway clearance 
but also to avoid having the timeframe be a confounding factor. FEV1 is still widely used as a 
marker of prognosis in CF, however LCI as an outcome measure has shown a rise in use in certain 
clinical trials involving new medication. Study II showed LCI to be more sensitive to changes 
than FEV1 after employing NIV as an adjunct to ACT. There are still but a few studies on airway 
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clearance where LCI is used as an outcome. Nevertheless, it could lead to a false result in those 
with very low FEV1 and completely obstructed airways. However, all the patients in this study 
were in a stable clinical condition.  
The present study offers a new approach to chest physiotherapy treatment in moderate to severe 
CF. In study III the aim was to describe the patients' perspective on and experience with using 
NIV. The results offer a deeper understanding of how patients experiences using NIV as an 
adjunct to ACT and may help the physiotherapist in the implementation and management of NIV. 
The physiotherapist is considered to play a significant role in the support of people with CF. 
During the study, it was revealed that participants felt motivated to perform ACT when combining 
it with NIV. Study IV showed a decrease in the rise of ptCO2 following NIV. The present study 
offers new treatment possibilities associated with exercise to adults with CF, thus allowing them 
to reach the physiological effects of physical training. 
The results of our studies showed that NIV may be applied to other respiratory diseases 
involving affected mucociliary clearance, and as assisted-exercise to compensate for the 
ventilaroty limitations. Our population of CF patients, of which 64 % were adults, displayed 
good lung function; nevertheless these patient caracteristics should also be applicable to other 
countries.  
 
5.4 FUTURE STUDIES   
In the studies mentioned here we showed that the timeframe following the spirometry have to be 
taken into account when designing future clinical and pharmaceutical trials. Additionally, it 
suggested that LCI may be a more sensitive early marker and stronger indicator of disease 
progression than spirometry. Further research is needed to evaluate the completed collapsed areas 
not envolved in the gas washout. 
During a three month trial, NIV as an adjunct to ACT was shown to be a good alternative to PEP;  
additional long-term studies are however needed in order to evaluate the effects of NIV in 
airway clearance and mucus transport. Our research revealed that participants felt motivated to 
perform ACT when done with the help of NIV. An interesting question to be addressed in future 
research is what role the presented findings play in the patient's long-term adherence to treatment. 
Clinical experience suggests that adherence to ACT has been improved, but further research is 
required in order to confirm. Another issue worth further study is how children with CF 
experience treatment when using NIV in their ACT. In this study, only adult patients were 
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recruited, as this was one of the very first qualitative studies to investigate the experience of using 
NIV as an ACT in CF. Future studies should examine the experience of other groups of patients 
with lung disease in order to obtain their views on chest physiotherapy interventions with NIV, 
thus optimizing the treatment. 
Physical training plays a significant part in the CF treatment package already, and patient survival 
rate is associated with fitness level. As a result, CF patients are encouraged to do physical exercise 
on the regular. NIV as support during exercise is effective, but more trials are needed to evaluate 
the long-term effects following the training period. 
Another important thing to evaluate further is the use of new therapies that modifies CFTR 
which creates a new spectrum regarding chest physiotherapy treatment and necessity of ACT in 
patients with CF. The increased knowledge of how CFTR dysfunction causes lung disease has 
resulted in new exciting targets for treatment. New therapies are being developed to target 
mutant CFTR and restore CFTR function. Clinical trials testing are divided in different 
cathegories as: gene therapy, mRNA repair, and CFTR modulators (ataluren, lumacaftor, 
ivacaftor – others are in pipeline for phase 3 studies). How these new therapies will affect the 
use of chest physiotherapy for optimal treatment needs to be investigated. 
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6 CONCLUSION  
This thesis has shown that: 
 The optimal timeframe for performing accurate spirometry following an airway 
clearance session varies between individual patients. However, the individual peak time 
also has to be taken into account. 
 For patients who are moderately to severely ill, NIV is a good alternative to PEP as an 
adjunct to ACT.  
 "Becoming friends with NIV" emerged as the overall theme of the studies. The theme may 
be seen to represent an individual learning process whereas the categories stand in for 
different aspects that facilitate learning, and should thus be considered individually. The 
physiotherapist plays an important supporting role during this learning process. The 
patients' experience with NIV treatment as an adjunct to ACT was often seen as a 
meaningful one. Understanding these experiences may facilitate the physiotherapist in the 
work with implementing NIV. Knowing which aspects to consider will help the 
physiotherapist make the patient's experience of NIV a meaningful one. 
 Non invasive ventilation is as good as oxygen supplementation when used by severely ill 
patients during an exercise test. The NIV treatment showed a decrease in the rise of 
tcPCO2, which kept the tcPCO2 levels within the normal reference values when compared 
with O2 supplementation.  
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